Clinical effect of tenofovir disoproxil fumarate versus entecavir in treatment of treatment-naïve patients with chronic HBV infection

Zhang JiaWei; Geng JiaBao; Lu Feng; Dong Yu

doi:10.3969/j.issn.1001-5256.2018.02.011

Issue 2

Feb. 2018

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2018 > 34(2): 272-275

PDF( 1559 KB)

Clinical effect of tenofovir disoproxil fumarate versus entecavir in treatment of treatment-naïve patients with chronic HBV infection

DOI: 10.3969/j.issn.1001-5256.2018.02.011

Department of Infectious Diseases, Zhoukou Central Hospital

Published Date: 2018-02-20

Abstract

Abstract

Objective To investigate the antiviral effect of tenofovir disoproxil fumarate (TDF) versus entecavir (ETV) in the treatment of treatment-nave patients with chronic HBV infection.Methods A total of 420 treatment-nave patients with chronic HBV infection or liver cirrhosis who received antiviral therapy with TDF or ETV and were regularly followed up in Zhoukou Central Hospital or Bayi Hospital Affiliated to Nanjing University of Chinese Medicine from July 2014 to July 2015 were enrolled, and among these patients, 184 received TDF (TDF group) and 236 received ETV (ETV group) .Laboratory markers were measured at baseline and at weeks 4, 8, 12, 24, and 48 of treatment, including liver and renal function parameters, blood calcium, serum phosphate, creatine kinase, HBV DNA level, hepatitis markers (HBs Ag, HBeAg, and anti-HBe) .Adverse drug reactions were also monitored.The t-test was used for comparison of continuous data between groups, and the chi-square test or Fisher's exact test was used for comparison of categorical data between groups.Results At week 48 of treatment, there were no significant differences between the two groups in HBeAg clearance rate among both HBeAg-positive patients and HBeAg-positive patients with HBV DNA > 6 lg IU/ml (P > 0.05) .There were also no significant differences between the two groups in alanine aminotransferase normalization rate among HBeAg-negative patients, HBeAg-positive patients, and HBeAg-positive patients with HBV DNA > 6 lg IU/ml (P > 0.05) .Both groups had a gradual reduction in HBV DNA level after the antiviral therapy.At week 48 of treatment, there were significant differences between the TDF group and the ETV group in the proportion of patients with a HBV DNA level below the lower limit of detection among HBeAg-positive patients (75.5% vs 60.8%, χ2= 5.857, P = 0.016) and HBeAg-positive patients with HBV DNA > 6 lg IU/ml (75.7% vs 60.5%, χ2= 5.722, P = 0.017) .At week 96 of treatment, the TDF group had a significantly higher rate of HBV DNA below the lower limit of detection than the ETV group among all patients (93.5% vs 86.9%, χ2=4.921, P = 0.027) , HBeAg-positive patients (89.1% vs 76.2%, χ2= 6.781, P = 0.009) , and HBeAg-positive patients with HBV DNA > 6 lg IU/ml (88.3% vs 73.7%, χ2= 7.456, P = 0.006) .Conclusion In HBeAg-positive patients with chronic HBV infection, TDF has a better inhibitory effect on HBV DNA than ETV, especially in those with HBV DNA > 6 lg IU/ml.
- hepatitis B, chronic,
- tenofovir disoproxil fumarate,
- entecavir,
- treatment outcome

FullText(HTML)

References(19)

References

[1]SARIN SK, KUMAR M, LAU GK, et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update[J].Hepatol Int, 2016, 10 (1) :1-98.

[2]YAN YP, SU HX, JI ZH, et al.Epidemiology of hepatitis B virus infection in China:current status and challenges[J].J Clin Transl Hepatol, 2014, 2 (1) :15-22.

[3]LOK AS, MCMAHON BJ.Chronic hepatitis B:update 2009[J].Hepatology, 2009, 50 (3) :661-662.

[4]SCHUTTE K, BALBISI F, MALFERTHEINER P.Prevention of hepatocellular carcinoma[J].Gastrointest Tumors, 2016, 3 (1) :37-43.

[5]XU W, YU J, WONG VW.Mechanism and prediction of HCC development in HBV infection[J].Best Pract Res Clin Gastroenterol, 2017, 31 (3) :291-298.

[6]WANG FM, LIU JT.Clinical efficacy of entecavir combined with Ganfule capsules in treatment of 80 cases of chronic hepatitis B with hepatic fibrosis[J/CD].Chin J Liver Dis:Electronic Edition, 2016, 8 (2) :95-98. (in Chinese) 王芳梅, 刘金涛.恩替卡韦联合肝复乐胶囊治疗慢性乙型肝炎肝纤维化80例疗效观察[J/CD].中国肝脏病杂志:电子版, 2016, 8 (2) :95-98.

[7]ZHANG Y, YU YS, TANG ZH, et al.Clinical study of entecavir combined with kushenin improving the Th1/Th2 imbalance in patients with HBeAg-positive chronic hepatitis B[J].Chin J Clin Pharmacol Ther, 2016, 21 (10) :1168-1172. (in Chinese) 张毅, 余永胜, 汤正好, 等.恩替卡韦联合苦参素改善HBeAg阳性慢性乙型肝炎患者Th1/Th2失平衡临床研究[J].中国临床药理学与治疗学, 2016, 21 (10) :1168-1172.

[8]Chinese Society of Hepatology and Chinese Society of Infectious Diseases Chinese, Medical Association.The guideline of prevention and treatment for Chronic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[9]FAN R, SUN J, HOU JL.Antiviral therapy for chronic hepatitis B:current status and perspectives[J].J Clin Hepatol, 2016, 32 (11) :2029-2032. (in Chinese) 樊蓉, 孙剑, 侯金林.慢性乙型肝炎抗病毒治疗现状及展望[J].临床肝胆病杂志, 2016, 32 (11) :2029-2032.

[10]HA NB, TRINH HN, ROSENBLATT L, et al.Treatment outcomes with first-line therapies with entecavir and tenofovir in treatmentnaive chronic hepatitis B patients in a routine clinical practice[J].J Clin Gastroenterol, 2016, 50 (2) :169-174.

[11]IDILMAN R, GUNSAR F, KORUK M, et al.Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-na6ve chronic hepatitis B patients in the real-world setting[J].J Viral Hepat, 2015, 22 (5) :504-510.

[12]BATIREL A, GUCLU E, ARSLAN F, et al.Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-na6ve patients with chronic hepatitis B:a multicenter real-life study[J].Int J Infect Dis, 2014, 28 (11) :153-159.

[13]OZARAS R, METE B, CEYLAN B, et al.First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment[J].Eur J Gastroenterol Hepatol, 2014, 26 (7) :774-780.

[14]GAO L, TRINH HN, LI J, et al.Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA[J].Aliment Pharmacol Ther, 2014, 39 (6) :629-637.

[15]YOO EH, CHO HJ.Clinical response to long-term tenofovir monotherapy in Korean chronic hepatitis B patients[J].Clin Chim Acta, 2017, 471 (8) :308-313.

[16]MURAT K, FATMA S, YESIM A, et al.Head-to-head comparison of two years efficacy of entecavir and tenofovir in patients with treatment-na6ve chronic hepatitis B--The real life data[J].Hepatogastroenterology, 2015, 62 (140) :982-986.

[17]CHANG TT, GISH RG, de MAN R, et al.A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B[J].N Engl J Med, 2006, 354 (10) :1001-1010.

[18]MARCELLIN P, HEATHCOTE EJ, BUTI M, et al.Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B[J].N Engl J Med, 2008, 359 (23) :2442-2455.

[19]LOPEZ CENTENO B, COLLADO BORRELL R, PEREZ ENCINAS M, et al.Comparison of the effectiveness and renal safety of tenofovir versus entecavir in patients with chronic hepatitis B[J].Farm Hosp, 2016, 40 (4) :279-286.

Relative Articles

[1]	Xin DAI, Hanlin LIU, Long CHENG, Zhulin LUO, Tao WANG. Association of programmed death-1 and programmed death-ligand 1 with the prognosis and clinical features of patients with hepatocellular carcinoma: A meta-analysis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1577-1583. doi: 10.3969/j.issn.1001-5256.2022.07.022
[2]	Liangliang GAN, Jinzhou ZHANG, Xiandong WANG, Caihong FU, Jia SU, Xuemei TANG. Efficacy of artificial liver support system in treatment of acute-on-chronic liver failure: A network Meta-analysis[J]. Journal of Clinical Hepatology, 2022, 38(1): 135-140. doi: 10.3969/j.issn.1001-5256.2022.01.021
[3]	Xin DAI, Hanlin LIU, Qiang WANG, Peng SHU, Long CHENG, Tao WANG. Short-term efficacy and safety of Da Vinci robotic pancreaticoduodenectomy versus traditional laparoscopic pancreaticoduodenectomy: A meta-analysis[J]. Journal of Clinical Hepatology, 2022, 38(5): 1106-1113. doi: 10.3969/j.issn.1001-5256.2022.05.025
[4]	Zhiran YANG, Linheng WANG, Yuan LI, Fusheng LIU, Yu WANG, Jianfang WANG, Runhua CHEN. Diagnostic value of transient elastography in the staging of hepatic fibrosis in patients with autoimmune liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2022, 38(1): 97-103. doi: 10.3969/j.issn.1001-5256.2022.01.015
[5]	Fei LIU, Hai LI, Qiang WU. Risk factors for bile leakage after hepatectomy without biliary reconstruction: A Meta - analysis[J]. Journal of Clinical Hepatology, 2022, 38(3): 594-600. doi: 10.3969/j.issn.1001-5256.2022.03.019
[6]	Ying LIU, Benjian GAO, Xiaoli YANG, Cheng FANG, Song SU, Bo LI. Effect of hemihepatic vascular exclusion versus total hepatic vascular exclusion in hepatectomy for primary liver cancer: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(1): 73-78. doi: 10.3969/j.issn.1001-5256.2021.01.015
[7]	Quan ZHOU, Lihui YANG, Fangqing JIANG. Long-term prognosis of patients with hepatitis C virus-related hepatocellular carcinoma receiving direct-acting antiviral: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(8): 1836-1840. doi: 10.3969/j.issn.1001-5256.2021.08.018
[8]	Yisheng PENG, Pan HE, Gang ZHU, Xinkai LI, Shunde TAN, Jianfei CHEN, Jun FAN, Bin LUO, Song SU, Bo LI, Xiaoli YANG. Efficacy and safety of CalliSpheres microsphere versus conventional transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(8): 1841-1847. doi: 10.3969/j.issn.1001-5256.2021.08.019
[9]	Tingpeng HU, Sudan TANG, Zebo YU. Relationship between vitamin D level in children and adolescents with nonalcoholic fatty liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(3): 627-631. doi: 10.3969/j.issn.1001-5256.2021.03.024
[10]	Shun ZHU, Zhiguo LI, Shuo LI, Xu CAO, Xiaobin LI, Xiaoke LI, Yongan YE. Effect of aspirin on the incidence rate of liver cancer in patients with viral hepatitis: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(5): 1097-1102. doi: 10.3969/j.issn.1001-5256.2021.05.024
[11]	Deliang HUANG, Wei DAI, Jun CHEN, Xiaoguang YE. Clinical features of liver injury induced by anti-tuberculosis drugs and related risk factors[J]. Journal of Clinical Hepatology, 2021, 37(10): 2369-2375. doi: 10.3969/j.issn.1001-5256.2021.10.022
[12]	Sun DongXue, Yang Zhu, Long FengXi, Wei XianMan, Tang DongXin. Efficacy and safety of Kanglaite injection combined with transarterial chemoembolization in treatment of advanced liver cancer: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(2): 363-368. doi: 10.3969/j.issn.1001-5256.2020.02.026
[13]	Liu ShenShen, Xing YiQing, Wang Ning, Yu QiaoLing, Ceng LePing. Clinical effect of vitamin E in treatment of nonalcoholic fatty liver disease in children: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(7): 1545-1550. doi: 10.3969/j.issn.1001-5256.2020.07.019
[14]	Wang XiangHong, Ma BaoHua, Zou XiuLan, Yao KeCheng, He Qian. Association between nonalcoholic fatty liver disease and epicardial adipose tissue: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(6): 1304-1309. doi: 10.3969/j.issn.1001-5256.2020.06.023
[15]	Tian Bing, Li Fan, Deng BaoCheng. Clinical effect of artificial liver support system in treatment of drug-induced liver failure: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(4): 823-828. doi: 10.3969/j.issn.1001-5256.2020.04.023
[16]	Qian Le, Ying Li. Selection of second-line drugs for adult autoimmune hepatitis: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(9): 2015-2020. doi: 10.3969/j.issn.1001-5256.2020.09.021
[17]	Lai Li, Peng FangYi, Su Song, Fang Cheng, Zhang MengYu, He Kai, Li Bo, He Pan, Xia XianMing. Clinical effect of robotic versus laparoscopic splenectomy in treatment of nontraumatic splenic diseases:A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2281-2285. doi: 10.3969/j.issn.1001-5256.2019.10.030
[18]	Sun Ying, Li RunPu, Wang XiaoJie. Correlation between liver damage degree and clinical manifestations in patients with pulmonary tuberculosis after chemotherapy[J]. Journal of Clinical Hepatology, 2015, 31(7): 1110-1113. doi: 10.3969/j.issn.1001-5256.2015.07.027
[19]	Zhang MingYuan, Lei JianPing, Yan ShiMing, Zhang WenHong, Huang YiXin, Niu JunQi. Liver injury induced by anti-tuberculosis drugs and anti-tuberculosis therapy for patients with liver disease: introduction of the experience of diagnosis and treatment in Chinese mainland and “Taiwan Guidelines for TB Diagnosis & Treatment”[J]. Journal of Clinical Hepatology, 2015, 31(11): 1776-1781. doi: 10.3969/j.issn.1001-5256.2015.11.004
[20]	Shen ShuiYing, Wu Jun. Acute liver failure caused by antitubercular drugs: a report of one case[J]. Journal of Clinical Hepatology, 2015, 31(9): 1483-1484. doi: 10.3969/j.issn.1001-5256.2015.09.029

Supplements(0)

Cited By

Cited by

Periodical cited type(5)

1.	许俊翱，黄艳雯，金满春. 水飞蓟素治疗临床肝病的疗效和不良反应分析. 系统医学. 2024(20): 66-69 .
2.	万丽红，张静，陈爽，赵萍. 替诺福韦酯联合复方益肝灵片对肺结核合并HBV携带患者免疫功能及肝肾功能的影响. 临床和实验医学杂志. 2023(18): 1938-1942 .
3.	管斌，朱建荣. 水飞蓟宾预防抗结核药物所致肝损伤的效果及安全性Meta分析. 中国热带医学. 2021(05): 496-500 .
4.	赵红，吕芳芳，桑荣霞，王晓忠，李志惠，谢雯. 水飞蓟宾胶囊治疗药物性肝损伤的临床疗效. 甘肃医药. 2021(06): 490-493 .
5.	金小琳，杨智彬，詹淑华，朱丹，何海英，殷水泽，马世武. 1501例初治住院结核病患者肝功能异常的影响因素. 中华实验和临床感染病杂志(电子版). 2020(05): 394-400 .

Other cited types(3)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (3484) PDF downloads(545)

Clinical effect of tenofovir disoproxil fumarate versus entecavir in treatment of treatment-naïve patients with chronic HBV infection

DOI: 10.3969/j.issn.1001-5256.2018.02.011